Lunai Bioworks (NASDAQ:LNAI) Trading Down 2.1% – Here’s What Happened

Posted by George Bondi on Aug 28th, 2026

Shares of Lunai Bioworks Inc. (NASDAQ:LNAI – Get Free Report) dropped 2.1% on Thursday . The company traded as low as $2.34 and last traded at $2.35. 39,837 shares traded hands during trading, a decline of 92% from the average session volume of 488,892 shares. The stock had previously closed at $2.40.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Wall Street Zen raised shares of Lunai Bioworks to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lunai Bioworks in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Read Our Latest Research Report on Lunai Bioworks

Lunai Bioworks Price Performance

The company has a market capitalization of $10.65 million, a price-to-earnings ratio of -5.88 and a beta of 0.41. The stock has a 50 day simple moving average of $2.68 and a two-hundred day simple moving average of $2.94.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Lunai Bioworks stock. Millennium Management LLC bought a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks as of its most recent SEC filing. 71.41% of the stock is currently owned by institutional investors and hedge funds.

Lunai Bioworks Company Profile

(Get Free Report)

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.